Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: ROG.SIX
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Roche Holding (ROG) Stock Forecast and AI Rating

Deep analysis published Sep 20 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

380 CHF

+6.4%+8.9% incl. dividends

2031

5-Year

BUY

491 CHF

+37.5%+54.1% incl. dividends

Published batch insight

Currency Drag Masks Biopharma Expansion As Metabolic Optionality Drives Valuation Recovery

Research reveals sharp divergence between optical headline stagnation and resilient constant-currency expansion. The primary driver is robust commercial volume in newer blockbusters paired with late-stage metabolic optionality, while persistent Swiss franc strength and looming post-2028 loss-of-exclusivity cliffs represent the decisive structural frictions across the forecast horizon.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Michael Burry (Vulture), Warren Buffett (Value Purist), Machiavelli (Insider), Superintelligence (Anthropologist), Elon Musk (Visionary), Ray Dalio (Strategist), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Roche Holding at publication: $16,165 in five years versus $13,892 for S&P 500 benchmark.

Roche Holding · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.3% net dividend yield for Roche Holding.

Figure: Five-year synthesized consensus value path for Roche Holding compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in CHF; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 356.8 CHF1-year price return: +6.41%5-year price return: +37.52%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in CHF, with returns and rationale
Quarter / date	Target (CHF)	Quarter return	Total return	Forecast rationale
Q118 Dec 2026	361.24	+1.25%	+1.25%	Commercial momentum across Vabysmo and subcutaneous oncology formulations supports defensive accumulation into year-end. However, ongoing safe-haven Swiss franc strength and high sovereign yields temper near-term valuation multiples, resulting in measured baseline equity appreciation.
Q218 Mar 2027	365.74	+1.25%	+2.51%	Full-year results confirm robust constant-currency operating expansion alongside another dividend increase. The seasonal ex-dividend price adjustment and currency translation drag partially offset underlying operational enthusiasm, keeping net price movement modest across Swiss trading desks.
Q318 Jun 2027	374.92	+2.51%	+5.08%	Advancing Phase Three enrollment for incretin candidates and positive oncological presentations at medical congresses bolster pipeline sentiment. Expanding adoption of subcutaneous biologics stabilizes pharmaceutical operating margins, driving steady institutional demand as market participants digest macroeconomic crosscurrents.
Q418 Sept 2027	379.66	+1.26%	+6.41%	Mid-year financial disclosures demonstrate solid diagnostics reagent cash flow and resilient specialty drug volumes. However, headlines regarding US Medicare price negotiations and European biosimilar competition introduce valuation friction, leading to tight consolidation near prevailing levels.
Q518 Dec 2027	387.50	+2.07%	+8.61%	Regulatory filing acceptances for key oncology line extensions and encouraging biomarker data stimulate defensive investment. Global monetary tightening continues to favor high-free-cash-flow pharmaceutical champions over speculative biotechs, sustaining modest upward trajectory into year-end portfolio positioning.
Q618 Mar 2028	391.05	+0.92%	+9.60%	Fiscal 2027 results highlight resilient cash conversion and another dividend increase. The seasonal dividend payout mechanically reduces the quoted price, while the start of negotiated pricing under US Medicare frameworks keeps institutional multiples disciplined.
Q718 Jun 2028	400.86	+2.51%	+12.35%	Interim clinical readouts for enicepatide and trontinemab generate commercial optimism, confirming pipeline vitality. Maturing launch products comfortably replace off-patent oncology attrition, enabling the stock to recover post-dividend declines and post steady operational price gains.
Q818 Sept 2028	407.90	+1.75%	+14.32%	Diagnostics automated testing expansion across North America and Europe stabilizes division operating profits above historical averages. While persistent Swiss franc translation friction caps reported earnings acceleration, consistent constant-currency execution provides reliable valuation support.
Q918 Dec 2028	412.01	+1.01%	+15.47%	Investor focus turns toward looming 2029 US tariff policy transitions and impending biologic patent expirations. High clinical R&D spending on metabolic outcome trials dampens quarterly operating margin expansion, producing a cautious, sideways trading pattern.
Q1018 Mar 2029	416.83	+1.17%	+16.83%	Annual disclosures for 2028 confirm underlying revenue growth and reliable cash generation, supporting the board's progressive dividend hike. Standard ex-dividend cash detachment is gradually absorbed by income-oriented institutional buyers seeking balance-sheet safety.
Q1118 Jun 2029	427.29	+2.51%	+19.76%	Pivotal Phase Three metabolic trial readouts establish competitive parity with market benchmarks, removing substantial pipeline skepticism. Sell-side analysts incorporate commercial incretin revenues into valuation models, sparking solid multiple expansion across European equity markets.
Q1218 Sept 2029	435.48	+1.92%	+22.05%	Global regulatory filings for enicepatide shift investor attention to pre-commercial scale-up and supply chain readiness. Emerging biosimilar competition against legacy intravenous formulations is effectively cushioned by rapid subcutaneous patient conversion, preserving quarterly profitability.
Q1318 Dec 2029	440.28	+1.10%	+23.40%	Preparations for commercial cardiometabolic launches accelerate alongside expanded diagnostics hospital contracts. Broader macroeconomic rotations into cash-generative healthcare assets support share prices, though cautious sentiment ahead of major patent expiries keeps valuation gains measured.
Q1418 Mar 2030	445.93	+1.28%	+24.98%	Full-year 2029 financial results show core operating margins holding above thirty-two percent despite statutory pricing pressure. The annual dividend increase reaffirms shareholder yield, while domestic manufacturing investments insulate operations from international trade friction.
Q1518 Jun 2030	452.58	+1.49%	+26.84%	Regulatory approvals for enicepatide in key Western markets unlock initial commercial prescription revenues. Early prescription uptake across commercial payer channels confirms launch viability, driving positive earnings revisions that comfortably outpace residual biosimilar erosion.
Q1618 Sept 2030	460.78	+1.81%	+29.14%	Commercial manufacturing scale-up for peptide synthesis and automated diagnostic systems lowers unit production costs. Stable healthcare spending across international territories cushions net operating income against ongoing domestic price renegotiations, sustaining moderate capital appreciation.
Q1718 Dec 2030	468.56	+1.69%	+31.32%	Accelerating cardiometabolic sales and expanding neurology indications diversify the consolidated earnings foundation. Management maintains conservative leverage and disciplined capital returns, prompting institutional long-term asset managers to expand core equity allocations into year-end.
Q1818 Mar 2031	473.73	+1.10%	+32.77%	Reporting for fiscal 2030 demonstrates record free cash flow generation and successful absorption of major patent transitions. Another progressive dividend hike rewards shareholders, while the predictable ex-dividend price adjustment is rapidly absorbed by persistent institutional buying.
Q1918 Jun 2031	482.76	+1.91%	+35.30%	Commercial scale in metabolic therapies combines with high-margin automated diagnostics to generate strong operational cash conversion. Second-generation oncology assets progress smoothly through clinical development, maintaining high visibility over medium-term corporate earnings compounding.
Q2018 Sept 2031	490.68	+1.64%	+37.52%	Terminal period performance confirms a successfully navigated five-year replacement cycle. High-margin specialty therapeutics and diagnostic platform integration establish an enduring cash compounder, settling equity valuation at an equilibrium multiple that rewards long-term capital providers.

The core investment thesis centers on a durable replacement cycle where expanding commercial blockbusters and high-throughput diagnostics generate sufficient operating cash flow to overcome patent expirations on legacy biologics. While reported Swiss franc financial statements optically compress performance, underlying operational volume compounds at mid-single-digit constant-currency rates. Valuation sensitivity remains elevated because the non-voting equity certificate trades near nineteen times core earnings rather than a perceived bargain multiple. The primary counterargument highlights approaching patent walls on key immunology and oncology franchises alongside statutory US Medicare price negotiation and structural safe-haven currency translation drag.

Key insights

Subcutaneous drug reformulations and proprietary diagnostic instrumentation establish high clinical switching barriers that defend gross margins and delay biosimilar erosion across hospital networks.
Acquired incretin assets provide unpriced cardiometabolic optionality, yet commercial viability depends on pivotal Phase Three tolerability parity rather than headline weight-loss efficacy.
Disconnect between constant-currency profit expansion and reported Swiss franc results will persist until foreign exchange headwinds abate and domestic cost matching improves.

Deep Dive

Prevailing market consensus treats the business as an ex-growth defensive bond proxy burdened by looming patent expiries on foundational biologics, US Medicare price negotiation overhang, and relentless Swiss franc translation friction. Sell-side sentiment assumes newer launches cannot outpace patent erosion, while external commentary largely writes off its emerging obesity and Alzheimer's pipeline as tardy, speculative bets facing entrenched global incumbents.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value through modest underpricing, mistaking optical currency translation drag for operational decay. Analytical edge stems from recognizing that constant-currency operating profit expands robustly as second-wave blockbusters and automated diagnostics fully neutralize biosimilar erosion. However, uncritical claims of a deep valuation discount are flawed: vendor screens erroneously double trailing earnings, masking that the non-voting certificate trades around nineteen times core earnings rather than thirteen times. True alpha lies in unmodeled cardiometabolic and neurological pipeline optionality against durable through-cycle cash flow.

Repricing catalyst

The primary convergence catalyst arrives across 2027 and 2028 through pivotal Phase Three readouts for dual-incretin enicepatide and regulatory filings for oral SERD giredestrant. Concurrently, as foreign exchange base effects lap, reported Swiss franc operating profit will inflect positively. Hard-to-ignore clinical registration data will force sell-side analysts to incorporate metabolic peak sales into discounted cash flow models, confirming pipeline replacement velocity and prompting institutional multiple expansion.

Published consensus context

Macro regime alignment

The macroeconomic backdrop of restrictive monetary policy, sticky inflation, and elevated geopolitical volatility represents a mixed setup. Inelastic healthcare demand protects core operating cash generation, and a conservative balance sheet insulates financing. However, persistent safe-haven Swiss franc strength creates enduring translation drag on foreign earnings, while high risk-free discount rates restrain the valuation multiples investors pay for defensive yields.

Published consensus context

Advisor disagreement

Analytical disagreement centers on valuation baselines and the durability of the patent bridge. One perspective argues that the non-voting equity certificate is fundamentally undervalued at a perceived thirteen times earnings, expecting multiple expansion toward historical peaks as cardiometabolic assets de-risk. Conversely, the skeptical view proves that vendor data double-counts trailing figures and that the certificate trades near nineteen times core earnings, leaving little margin of safety against approaching Ocrevus patent expiries. Resolving this tension requires tracking whether reported Swiss franc earnings inflect positive in 2027 and whether Phase Three obesity trials confirm competitive tolerability.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Commercial expansion of core specialty blockbusters: High-margin commercial therapies anchored by Vabysmo, Phesgo, Ocrevus, and Hemlibra generate double-digit constant-currency growth, outpacing legacy biologic erosion. Subcutaneous lifecycle formulations protect market share by shifting patient administration away from hospital infusion chairs. This volume expansion sustains consolidated gross margins above seventy-three percent, securing robust operational cash flow through the patent cliff. Expected impact: +20%.
Incretin franchise advancement and pipeline rejuvenation: Advancement of dual-incretin enicepatide alongside oral candidate CT-996 into Phase Three registration trials unlocks long-term cardiometabolic optionality. Demonstrating competitive weight-loss efficacy and manageable tolerability positions the business to capture meaningful market share in an expanding metabolic domain. Successful commercial execution will provide a durable second growth pillar, expanding forward terminal value and driving multiple re-rating. Expected impact: +17%.
Integrated diagnostics platform and reagent compounding: An unmatched global installed base of automated laboratory platforms locks hospital networks into multi-year proprietary reagent contracts. This razor-and-blade model delivers non-cyclical, high-margin consumable cash flow that buffers pharmaceutical patent volatility. As clinical chemistry, molecular assays, and companion biomarker testing scale globally, recurring diagnostic earnings compound steadily, insulating consolidated operating margins against broader macroeconomic downcycles. Expected impact: +11%.
Disciplined capital allocation and dividend compounding: Generating over fourteen billion francs in annual free cash flow underpins an unbroken four-decade track record of growing Swiss franc dividends. Conservative balance-sheet stewardship prioritizes self-funded internal clinical development and selective bolt-on acquisitions rather than dilutive mega-mergers. This dependable capital distribution policy establishes an enduring valuation floor, attracting defensive institutional capital during volatile global interest rate regimes. Expected impact: +9%.

Top frictions and headwinds

Structural Swiss franc foreign exchange drag: Persistent safe-haven strength of the Swiss franc creates a perpetual negative translation wedge on reported financials. Generating over eighty percent of revenues in depreciating foreign currencies while maintaining substantial domestic research and corporate overhead mechanically compresses reported top-line expansion and nominal earnings. Constant-currency growth consistently fails to convert into equivalent reported franc figures, muting headline equity returns. Expected impact: -11%.
Impending loss of exclusivity patent cliffs: Expiring patent protections on foundational blockbusters, including Perjeta, Kadcyla, and Actemra, alongside approaching patent expirations on Ocrevus, create continuous structural revenue erosion. Aggressive biosimilar discounting forces the business to reinvest billions into clinical research merely to replace lost revenues. This relentless replacement cycle constrains net revenue acceleration and caps consolidated pharmaceutical operating margin expansion. Expected impact: -10%.
US and global healthcare pricing retrenchment: Mandatory Medicare drug price negotiations under the US Inflation Reduction Act, alongside European single-payer containment and Chinese volume-based procurement, squeeze net realized pharmaceutical prices. Statutory price caps on mature biologics degrade gross-to-net realizations in the company's most profitable geographic markets. This intensifying regulatory intervention limits long-term pricing flexibility, compressing terminal cash flows across mature commercial lines. Expected impact: -9%.
Escalating late-stage clinical trial expenditures: Funding expansive global Phase Three registration trials across cardiometabolic, oncological, and neurological indications elevates research and development intensity toward twenty-two percent of revenue. Escalating patient recruitment costs and complex trial protocols consume substantial operating cash flow before commercial revenues materialize. This heavy reinvestment burden temporarily suppresses free cash flow conversion, deferring operational margin expansion until commercialization milestones arrive. Expected impact: -7%.

Tail risks

Catastrophic late-stage obesity pipeline failure: Registrational trials for enicepatide or oral incretin CT-996 could uncover unexpected hepatotoxicity or severe gastrointestinal discontinuation rates during Phase Three escalation by 2027. Clinical termination would instantly wipe out acquired Carmot goodwill and extinguish market expectations of a multi-billion-franc cardiometabolic franchise. Probability remains under fifty percent given clean early-phase tolerability data, but biological development attrition poses a severe tail threat. Probability: +28%. Expected impact: -23%.
Radical transatlantic healthcare price cap mandate: Coordinated legislative escalation in the United States and Europe could aggressively expand mandatory price negotiations to capture newer biologics and subcutaneous reformulations before 2028. Enforcing draconian statutory reference pricing would severely collapse gross margins in primary profit pools, permanently impairing corporate cash generation. Legal friction and legislative inertia keep probability below thirty percent, but realization would severely impair enterprise valuation. Probability: +25%. Expected impact: -20%.

Tail opportunities

Pivotal Phase Three obesity trial triumph: Dual-incretin candidate enicepatide could deliver greater than twenty-four percent placebo-adjusted weight loss with superior muscle preservation and clean gastrointestinal tolerability in Phase Three registration trials by late 2028. This clinical breakthrough would disrupt the metabolic duopoly, unlocking over eight billion francs in unmodeled peak sales. Probability remains under fifty percent due to fierce incumbent competition and trial attrition. Probability: +32%. Expected impact: +26%.
Brainshuttle Alzheimer therapy clinical breakthrough: Proprietary Brainshuttle technology delivering trontinemab into the central nervous system could demonstrate rapid amyloid plaque clearance with negligible imaging abnormalities in pivotal trials by 2029. Successfully pairing this disease-modifying therapy with Elecsys blood biomarker diagnostic screening would unlock an unencumbered multi-billion-franc neurology franchise. Historical clinical attrition in Alzheimer's drug development caps event probability below thirty percent. Probability: +26%. Expected impact: +28%.

What to monitor

Thesis watchpoints

-- Confirmation: Vabysmo, Phesgo, and subcutaneous Ocrevus maintaining constant-currency revenue growth above ten percent through 2027 confirms organic patent-cliff replacement.

Key insights

Deterioration: Core operating margin contracting below twenty-eight percent across consecutive half-year reporting periods signals irreversible pricing erosion or clinical execution failure.
Reassessment: Enicepatide Phase Three obesity trial discontinuation or gastrointestinal dropout rates exceeding fifteen percent before late 2028 requires cutting metabolic valuation.

Company Financial Analysis

Roche Holding Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The headline earnings story seems confusing at first glance because reported Swiss franc revenues slipped while operating profits climbed. For fiscal 2025, reported sales edged down one percent to 61.5 billion Swiss francs, yet constant-currency sales expanded seven percent. Net profit rebounded sharply to 12.9 billion francs as prior-year write-downs faded. This performance shows that the underlying commercial engine is fundamentally sound. Rapid volume gains from newer blockbusters easily offset generic competition on older cancer therapies. Over fourteen billion francs in annual free cash flow proves that the business continues to generate high-quality, recurring cash.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	CHF 61.5B	CHF 12.9B	CHF 14.1B
2024	CHF 62.4B	CHF 8.3B	CHF 15.1B
2023	CHF 60.4B	CHF 11.5B	CHF 11.4B
2022	CHF 65.8B	CHF 12.4B	CHF 13.3B
2021	CHF 62.8B	CHF 13.9B	CHF 16B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	12.5x	TTM	Native	CHF / CHF
2024	10.4x	TTM	Native	CHF / CHF
2023	8.2x	TTM	Native	CHF / CHF
2022	18.7x	Annual	Native	CHF / CHF
2021	23.3x	Annual	Native	CHF / CHF

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profit margins demonstrated impressive resilience in 2025 as the company successfully transitioned away from post-pandemic disruptions. Gross margins held remarkably firm near seventy-four percent, proving that customer demand for proprietary specialty medicines remains insensitive to broader inflation. Operating margin rebounded sharply to thirty-one percent as temporary restructuring costs and inventory charges ended. Favorable product mix shifts toward premium specialty medicines and high-margin diagnostic reagents provide structural operating leverage. This dual-engine business model successfully defends company profitability against mandatory government pricing reforms and generic biosimilar competition.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	CHF 19.3B	31.3%	20.9%
2024	CHF 13.4B	21.5%	13.3%
2023	CHF 15.4B	25.5%	19.0%
2022	CHF 17.5B	26.6%	18.9%
2021	CHF 18.2B	28.9%	22.2%

Balance sheet and leverage

AI Review

The balance sheet provides an exceptionally sturdy financial shield that protects investors during turbulent economic conditions. Equity stood at nearly thirty-four billion francs in 2025, with conservative debt-to-equity below one. Solid operational cash flows cover interest obligations more than fourteen times over, guaranteeing effortless debt service. The primary regular cash commitment is the annual dividend, which absorbed over eight billion francs in 2025. While this distribution consumes a substantial portion of free cash flow, exceptional liquidity and staggered bond maturities ensure the company remains insulated from tightening global credit markets.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	CHF 33.2B	CHF 15.5B	CHF 27.6B net debt	1.38x
2024	CHF 36.4B	CHF 17.3B	CHF 29.4B net debt	1.48x
2023	CHF 30.8B	CHF 10.5B	CHF 25.4B net debt	1.35x
2022	CHF 26.5B	CHF 9.8B	CHF 21.6B net debt	1.24x
2021	CHF 32.6B	CHF 13B	CHF 25.7B net debt	0.93x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management maintains strict capital discipline when constructing physical facilities while directing substantial financial firepower into scientific research. In 2025, physical capital spending moderated to six percent of revenue, releasing cash back into the business after modernizing primary manufacturing plants. Instead of chasing risky mega-mergers, the company deployed over thirteen billion francs directly into targeted research and clinical trials. Strategic investments in automated diagnostics and late-stage obesity programs ensure that capital is concentrated on high-value innovations that protect future profit margins and deliver strong returns on invested capital.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	CHF 3.7B	CHF 13.4B
2024	CHF 5B	CHF 15.3B
2023	CHF 4.6B	CHF 14.2B
2022	CHF 4.6B	CHF 15.2B
2021	CHF 4.5B	CHF 14.8B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	159	+10.4%	Not available	ORIGINAL
5Y	BUY	166	+61.3%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	349.66	363.17	367.5	14
+6M	March 18, 2027	339.17	369.22	382.2	14
+9M	June 18, 2027	342.57	378.2	389.85	14
+1Y	September 18, 2027	335.71	384.81	401.54	14
+15M	December 18, 2027	325.64	392.36	409.57	14
+18M	March 18, 2028	319.13	397.94	421.86	14
+21M	June 18, 2028	325.51	408.51	434.31	14
+2Y	September 18, 2028	312.49	416.49	447.34	14
+27M	December 18, 2028	306.24	422.45	456.29	14
+30M	March 18, 2029	309.3	429.62	465.63	14
+33M	June 18, 2029	315.49	440.79	488.82	14
+3Y	September 18, 2029	318.65	449.05	498.6	14
+39M	December 18, 2029	318.65	455.69	503.59	14
+42M	March 18, 2030	325.02	463.33	513.66	14
+45M	June 18, 2030	328.27	472.24	529.07	14
+4Y	September 18, 2030	334.83	480.26	539.65	14
+51M	December 18, 2030	331.49	488.38	545.04	14
+54M	March 18, 2031	334.8	495.63	555.95	14
+57M	June 18, 2031	341.5	504.4	567.06	14
+5Y	September 18, 2031	344.91	512.72	573.17	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Frozen comparison context

USDCHF.FOREX forecast context

The batch's original inverse_usd_to_listing path is preserved for transparent interpretation of USD-normalized returns.

FX snapshot: 0.825 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	0.8333	0.835	0.8415
+6M	March 18, 2027	0.8333	0.8428	0.8583
+9M	June 18, 2027	0.8249	0.8434	0.8669
+1Y	September 18, 2027	0.8167	0.8417	0.8756
+15M	December 18, 2027	0.8003	0.8375	0.8843
+18M	March 18, 2028	0.7923	0.831	0.8932
+21M	June 18, 2028	0.7843	0.8269	0.9021
+2Y	September 18, 2028	0.7843	0.8235	0.9021
+27M	December 18, 2028	0.7764	0.8194	0.9021
+30M	March 18, 2029	0.7686	0.8136	0.8931
+33M	June 18, 2029	0.7686	0.8125	0.8931
+3Y	September 18, 2029	0.761	0.8085	0.8842
+39M	December 18, 2029	0.7457	0.8052	0.8842
+42M	March 18, 2030	0.7383	0.8018	0.8756
+45M	June 18, 2030	0.7383	0.7996	0.8843
+4Y	September 18, 2030	0.7309	0.7957	0.8843
+51M	December 18, 2030	0.7236	0.793	0.8843
+54M	March 18, 2031	0.7236	0.7908	0.8932
+57M	June 18, 2031	0.7164	0.7875	0.8931
+5Y	September 18, 2031	0.7092	0.7864	0.8842

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

Weighting allocations reflect evidentiary rigor, forensic accounting precision, and causal consistency across differing analytical horizons. An independently supported common pattern confirms that commercial blockbusters like Vabysmo and Phesgo generate double-digit constant-currency growth, effectively offsetting mature biologic biosimilar attrition and generating over fourteen billion francs in annual free cash flow. However, several evaluations exhibit correlated bias by accepting doubled trailing financial screen metrics uncritically, assuming an artificially depressed price-to-earnings multiple near thirteen times and an inflated cash yield. Higher weights are awarded to analyses that correct this reporting distortion, recognizing that the non-voting participation certificate trades near nineteen times core earnings, while thoroughly examining currency translation leakage and looming post-2028 patent expirations on Ocrevus. The credible contrarian case highlights that R&D outlays and US regulatory drug pricing will compress margins before obesity revenues materialize. These verified considerations appropriately anchor the synthesized scenario.

AI RESEARCHER

15.09%Weight

Universal Investor AI

The Polymath

Opus 5

Demonstrating premier analytical precision, this report untangles the arithmetic mismatch between high constant-currency growth and flat Swiss franc reported results. It forensically verifies US tariff suspension timelines and realistic trailing valuation multiples, providing an unassailable causal framework for mid-single-digit compounding that earns the co-highest weighting.

AI RESEARCHER

15.09%Weight

Universal Investor AI

The Polymath

GPT-6 Astra

This exceptional submission forensically identifies that ROP is a non-voting certificate and uncovers that vendor screening double-counts trailing data, proving ROP trades near nineteen times core earnings rather than thirteen. Its superior factual verification, realistic replacement cycle modeling, and disciplined margin analysis merit the highest relative weight.

AI RESEARCHER

9.43%Weight

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Demonstrating superior macro and through-cycle reasoning, this report accurately identifies how non-discretionary healthcare demand and fortress balance sheet liquidity provide defensive resilience in a restrictive rate regime. Its balanced return expectations appropriately reflect both foreign exchange translation headwinds and incremental pipeline contributions, justifying a prominent allocation.

AI RESEARCHER

7.55%Weight

Michael Burry AI

The Vulture

Gemini 3.8 Flash

The contrarian thesis diligently assesses looming Ocrevus patent expirations, heavy late-stage obesity R&D cash absorption, and persistent Swiss franc translation friction. While its severe terminal multiple derating appears excessively punitive given resilient diagnostics cash flow, its rigorous risk identification justifies a meaningful weight to discipline consensus optimism.

AI RESEARCHER

7.55%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Grounding its thesis in owner earnings and durable competitive moats, this perspective provides solid causal links between high-margin specialty biologics and reliable dividend progression. While it slightly underestimates Medicare price negotiation drag, its disciplined capital return analysis provides robust ballast against speculative pipeline assumptions.

AI RESEARCHER

5.66%Weight

Elon Musk AI

The Visionary

Gemini 3.8 Flash

This report provides strong causal reasoning on subcutaneous reformulation moats and incremental biologic volume gains. However, its valuation premise relies on unverified screen data indicating a thirteen times multiple, slightly diluting analytical precision. A moderate weight captures its sound insights on operational cash durability.

AI RESEARCHER

5.66%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

The report correctly highlights double-digit constant-currency expansion across newer therapies and the diagnostics division's cash resilience. Nevertheless, it uncritically adopts vendor-screen valuation metrics showing an exaggerated free cash flow yield, limiting its relative weight. Its clinical insights on enicepatide Phase Three execution remain sound and decision-useful.

AI RESEARCHER

5.66%Weight

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Providing valuable insight into family pool governance and non-voting capital allocation discipline, this evaluation explains management's ability to resist short-term pressures. However, its trajectory assumes rapid multiple expansion that understates post-2028 biosimilar headwinds, warranting a measured allocation that balances strategic strengths against commercial execution risks.

AI RESEARCHER

5.66%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

This evaluation details robust constant-currency volume momentum across core blockbusters while clearly separating reported headline figures from underlying operational performance. Its weight is tempered by an overly optimistic timeline for cardiometabolic commercialization, which underplays competitive entrenchment and clinical attrition in obesity trials.

AI RESEARCHER

5.66%Weight

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

This report provides strong forensic verification of diagnostics margin normalization and subcutaneous formulation defenses against biosimilar encroachment. However, its long-term forecast assumes exceptionally smooth metabolic commercialization and sustained multiple re-rating, warranting a moderate weight that values its operational scrutiny without endorsing its optimistic terminal trajectory.

AI THINKER

4.72%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

This submission presents a coherent analysis of the diagnostics razor-and-blade moat and family-governed reinvestment discipline. However, it shares correlated valuation assumptions with other value-oriented inputs while understating upcoming loss-of-exclusivity erosion on mature oncology assets, warranting a modest weight to prevent redundant perspective double-counting.

AI THINKER

4.72%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Providing solid evidence on biopharma inflection and diagnostics cash flow durability, this evaluation effectively explains how loss-of-exclusivity erosion is neutralized by second-wave blockbusters. However, it largely duplicates consensus drivers while accepting unadjusted trailing multiples, justifying a modest weight that captures its valid operational conclusions.

AI RESEARCHER

3.77%Weight

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

While offering detailed commercial appraisals of Vabysmo and cobas diagnostics, this perspective adopts an overly aggressive valuation re-rating toward historical peaks. It heavily discounts late-stage incretin clinical attrition and foreign exchange friction, necessitating a reduced weight to prevent upward trajectory distortion.

AI THINKER

3.77%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Offering vivid metaphors of biological monopoly and non-cyclical demand, this analysis accurately captures the inelasticity of oncology and diagnostics workflows. Nevertheless, it uncritically accepts duplicated screen multiples and models an aggressive multiple expansion path, requiring a lower weight to maintain disciplined valuation realism.

Research Provenance

References & Context

This Roche Holding consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 54 deduplicated sources retained for this batch.

01CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation | CMScms.gov
02CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs | CMScms.gov
03Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
04PROTHENA CORP PUBLIC LTD CO - Form DEF 14A - FY2026sec.gov
05Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
06Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure | AJMCajmc.com
07Roche Obesity Pipeline Enters Phase III With Enicepatideallsci.com
08Roche Annual Report 2025assets.roche.com
09Roche Diagnostics Day 2026assets.roche.com
10Trump's drug pricing program reaches 26 manufacturers after nine new additions - Biostockbiostock.se
11Roche HY 2026 slides: profit growth outpaces sales amid expansion By Investing.comca.investing.com
12US Pharmaceutical Tariffs and Most Favored Nation Policy: Implications for Drug Pricing and Supply Chainscboh.unc.edu
13A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
14Roche Holding AG ( ROG.SW) - Price Historydigrin.com
15Drug companies sign "Most Favored Nation" deals, then raise prices anywaydrugdiscoverytrends.com

And 39 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-12-31–2026-06-30, 6 periods

Currencies cited: CHF, USD (quote CHF; primary reporting CHF; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.